An orally administrable composition for treating or reducing damage to connective tissue or for treating or reducing inflammatory symptoms associated with damage to connective tissue includes a synergistic combination of: (i) avocado/soybean unsaponifiables; and (ii) lipoic acid, or a salt or derivative thereof. Methods for treating or reducing damage to connective tissue, for treating or reducing inflammatory symptoms associated with damage to connective tissue, or for reducing levels of one or more inflammatory mediators in connective tissue include administering the orally administrable composition to an avian or mammalian subject.
An anxiolytic composition formulated for oral administration to a mammal includes a synergistic combination of L-theanine, at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron. The composition may include a combination of an extract of Magnolia officinalis and a extract of Phellodendron amurense. The synergistic combination may provide an anxiolytic change in a release pattern of one or more brain neurotransmitters, such as glutamate and/or γ-aminobutyric acid (GABA).
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A nutritional supplemental for a human or animal, such as a dog or a cat, which includes a partially hydrophobic coating applied to a tablet, is provided. The tablet includes SAMe (S-Adenosylmethionine) milk thistle, and/or any other hydroscopic raw material. SAMe is typically used as an active ingredient to support the liver of the animal. The coating of the tablet typically includes a polymer or resin, stearic acid as a moisture barrier, and calcium carbonate. The coating may also include a plasticizer and color agent. The polymer or resin is typically hydroxypropyl methyl cellulose, and the plasticizer typically includes triethyl citrate and optionally lecithin.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
Compositions are described including a combination of hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-β-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for preventing or reducing an inflammatory response in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
On-line retail store services featuring dietary and nutritional supplements Dietary and nutritional supplements Providing information in the fields of health and wellness
A nutritional supplemental for a human or animal, such as a dog or a cat, which includes a partially hydrophobic coating applied to a tablet, is provided. The tablet includes SAMe (S-Adenosylmethionine) milk thistle, and/or any other hydroscopic raw material. SAMe is typically used as an active ingredient to support the liver of the animal. The coating of the tablet typically includes a polymer or resin, stearic acid as a moisture barrier, and calcium carbonate. The coating may also include a plasticizer and color agent. The polymer or resin is typically hydroxypropyl methyl cellulose, and the plasticizer typically includes triethyl citrate and optionally lecithin.
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
Phellodendron amurense. The synergistic combination may provide an anxiolytic change in a release pattern of one or more brain neurotransmitters, such as glutamate and/or γ-aminobutyric acid (GABA).
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A soft chew nutritional supplement for an animal, such as a dog or cat, is provided. The soft chew includes (a) palm oil and/or palm oil constituent, (b) palm kernel oil and/or coconut oil, and (c) at least one other oil. The method of manufacturing the soft chew typically includes partially curing the soft chew at -79 to 0°C before packaging the soft chew, and then allowing the soft chew to fully cure while in the packaging at room temperature. To achieve the desired processing and curing of the soft chew, the ratio of the total amount of the components (a) and (b) to the total amount of the (c) other oil ranges from 45:55 to 55:45. In addition, the components (a) and (b) have a Mettler Dropping Point ranging from 36oC to 40o C and are present in an amount of 4.5 wt. % to 6.5 wt. %.
A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present disclosure application relates to cannabis-containing compositions comprising at least one cannabinoid, provided in a gel formulation. The compositions may include cannabidiol. The source of the cannabidioid may be cannabis, a cannabis extract, or an industrial hemp oil extract. Methods of treating and/or reducing symptoms of an inflammatory response and/or inflammation are described, comprising administering to a subject in need thereof the disclosed compositions.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A composition including a Moringa plant component for treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of cancer in a subject is provided. The composition may comprise a Moringa plant component in an amount of 1 mg to 1750 mg, and sulforaphane or a sulforaphane derivative in an amount of 1 mg to 50 mg. Alternatively, the composition may comprise a Moringa plant component in an amount of 150 mg to 1500 mg sulforaphane precursor in an amount of 1 mg to 50 mg. The Moringa plant component can be Moringa leaf extract containing 10 mg of moringin per 1000 mg of the Moringa leaf extract. The composition may also include at least one of a mushroom extract or powder and a broccoli extract or powder.
MoringaMoringaMoringaMoringaMoringaMoringaMoringa leaf extract. The composition may also include at least one of a mushroom extract or powder and a broccoli extract or powder.
The present application relates to compositions comprising avocado/soybean unsaponifiables (“ASU”) and cannabis, and related methods of use. In one embodiment, the cannabis is a cannabis oil extract that is combined with ASU to reduce inflammatory responses and inflammation in humans and animals.
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Allergy medication; allergy tablets; amino acid dietary supplements; anti-oxidants for use as dietary supplements; digestive enzymes used to treat food allergies in pets; minerals; nutraceuticals for use as a dietary supplement for general health and well-being; nutritional supplements for animal foodstuffs; prebiotic supplements; probiotic supplements; protein supplements for animals; vitamins
(2) Dietary and nutritional supplements for human joint health and flexibility, for healthy immune system for humans; pharmaceuticals for veterinary use, namely, for the treatment of arthritis, of degenerative joint or bone diseases, conditions, or disorders, of nutrient, vitamin, or mineral deficiencies, and of diseases, conditions, or disorders related to the kidneys, liver, cardiovascular system, brain, immune system, nervous system, endocrine system, musculoskeletal system, reproductive system, respiratory system, digestive tract, urinary tract, skin, or coat; Dietary, nutritional and herbal supplements for animal use for joint and bone health, for liver health, for digestive health, for skin and coat health, for brain health, for function, for urinary health, for heart health, to support renal function, to support nervous system function, for immune system function and for dental health; Dietary, nutritional and herbal supplements to treat skin allergies in animals. (1) Wholesale and online sale of pharmaceutical preparations and dietary, nutritional and herbal supplements for animal and human use via a website; Providing information on dietary, nutritional and herbal supplements for animal and human use via a website
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplement for eliminating toxins from the intestinal tract; dietary supplements for general health and well-being; digestive enzymes used to treat exocrine pancreatic insufficiency (EPI) for veterinary purposes; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; nutritional supplements for maintaining a healthy digestive system; vitamin supplements; vitamins
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Shampoos; skin care preparations; skin creams
(2) Allergy medication; allergy medications; anti-inflammatories; antifungal creams for medical purposes; antihistamines; antimicrobials for dermatologic use; antiseptics; decongestants; dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplements for general health and well-being; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; pharmaceutical preparations for treating allergies; topical anti-inflammatories; vitamin supplements; vitamins
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplement for eliminating toxins from the intestinal tract; dietary supplements for general health and well-being; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; nutritional supplements for maintaining a healthy digestive system; probiotic supplements; vitamin supplements; vitamins
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplement for eliminating toxins from the intestinal tract; dietary supplements for general health and well-being; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; nutritional supplements for maintaining a healthy digestive system; vitamin supplements; vitamins
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antioxidant supplements for pets; dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplement for eliminating toxins from the intestinal tract; dietary supplements for general health and well-being; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; nutritional supplements for maintaining a healthy digestive system; vitamin supplements; vitamins
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Botanical supplements for general health and well-being; dietary and nutritional supplements for general health and wellbeing; dietary supplements consisting of amino acids; dietary supplements consisting of trace elements; dietary supplements for general health and well-being; herbal supplements for general health and well-being; minerals; nutritional supplements for general health and well-being; vitamin and mineral supplements; vitamins
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Dietary and nutritional supplements to support joint health in animals; dietary pet supplements in the form of pet treats to support joint health in animals
The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Edible preparations, namely, a pliable paste and dough like substance for the delivery of medicine and nutritional supplements to animals sold without medicine
The present disclosure application relates to cannabis-containing compositions comprising at least one cannabinoid, provided in a gel formulation. The compositions may include cannabidiol. The source of the cannabidioid may be cannabis, a cannabis extract, or an industrial hemp oil extract. Methods of treating and/or reducing symptoms of an inflammatory response and/or inflammation are described, comprising administering to a subject in need thereof the disclosed compositions.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
85.
Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and magnesium or a salt or complex thereof. The invention also relates to the combination of a broccoli extract or powder and magnesium or a salt or complex thereof. The invention provides compositions and methods relating to these combinations.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Nutritional proprietary ingredient blend comprised of mushroom extract and yeast extract for use as an ingredient in the manufacture of dietary supplements
90.
Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder
The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for preventing or reducing an inflammatory response in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
96.
Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
An orally administrable composition for treating or reducing damage to connective tissue or for treating or reducing inflammatory symptoms associated with damage to connective tissue includes a synergistic combination of: (i) avocado/soybean unsaponifiables; and (ii) lipoic acid, or a salt or derivative thereof. Methods for treating or reducing damage to connective tissue, for treating or reducing inflammatory symptoms associated with damage to connective tissue, or for reducing levels of one or more inflammatory mediators in connective tissue include administering the orally administrable composition to an avian or mammalian subject.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
